HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more
HANSOH PHARMAC. HD-00001 (3KY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, HANSOH PHARMAC. HD-00001 (3KY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
HANSOH PHARMAC. HD-00001 - Net Assets Trend (None–None)
This chart illustrates how HANSOH PHARMAC. HD-00001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HANSOH PHARMAC. HD-00001 (None–None)
The table below shows the annual net assets of HANSOH PHARMAC. HD-00001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to HANSOH PHARMAC. HD-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
HANSOH PHARMAC. HD-00001 Competitors by Market Cap
The table below lists competitors of HANSOH PHARMAC. HD-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Option Care Health Inc
NASDAQ:OPCH
|
$4.44 Billion |
|
Radian Group Inc
NYSE:RDN
|
$4.44 Billion |
|
FPT Corp
VN:FPT
|
$4.44 Billion |
|
Informatica Inc
NYSE:INFA
|
$4.44 Billion |
|
Boyd Gaming Corporation
NYSE:BYD
|
$4.44 Billion |
|
Tokyu Fudosan
F:T8F
|
$4.44 Billion |
|
Punjab National Bank
NSE:PNB
|
$4.44 Billion |
|
Janus Henderson Group PLC
NYSE:JHG
|
$4.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HANSOH PHARMAC. HD-00001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares HANSOH PHARMAC. HD-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently HANSOH PHARMAC. HD-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares HANSOH PHARMAC. HD-00001's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HANSOH PHARMAC. HD-00001 (3KY) | €- | N/A | N/A | $4.44 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |